About SKLBE

Members

Home>> About SKLBE >> Members

Xingyuan Ma

CreatedTime：2018-09-06 10:09:00

Dr. Xingyuan Ma,

Professor of molecular & cellar Biology and Biomedcines

Dept. of Biochemistry, SchoolofBioengineering

State Key Laboratory of Bioreactor Engineering (SKLBE)

East ChinaUniversity of Science and Technology (ECUST)

130 Meilong Road, P.O. Box No. 365
Shanghai, 200237, P. R. China

Tel & Fax: 86-21-64250135

Email: maxy@ecust.edu.cn maxingyuan@hotmail.com

Education and Research Experiences:

2012.---: Professor. Molecular & Cellar Biology and Genetic engineering drugs, Dept. of Biotechnology, ECUST,

2010.12/2011.11: Visiting Scholar. Novel drugs of anticancer and its stem cells Molecular Biology and Genetic engineering, National University of Singapore (NUS)

2008.9/2010.11: Associate Professor. Molecular & Cellar Biology and Genetic engineering anticancer drugs, Dept. of Biotechnology, ECUST

2005.10/2008.8: Associate Professor. Molecular & Cellar Biology and Genetic engineering,CollegeofBiotechnology, ECUST

2003.9/2005.9: Post-Doc Researcher. Molecular Biology and Genetic engineering,InstituteofBiochemistry, ECUST

1999.9/2003.6: Ph. D. Microbial Molecular Biology,QuartermasterUniversityof PLA

1999.7/2003.9: Teacher Study and teaching on animal medicine and science in AUS

1996.9/1999.7: M. Sc Animal Medicine, Agricultural University ofShenyang(AUS)

1995.7/1996.9: Pre-M. Sc work. Working on Husbandry Bureau ofXingCounty, Shan’xi

1991.9/1995.7: B. Sc Animal Medicine, AgriculturalUniversityofShan’xi

Research Interests:

1. Prof. Ma devoted to the researches of molecular & cellar biology in cancer and its stem cells for R&D of novel drugs of anticancer by analyses changing on tumor cell physiology, cytometry, cellular structures and microscopy recently.

2. He also focused on following research program including recombinant proteins (Drugs/Vaccine/Antibody) and pharmaceutical biotechnology from genetic engineering based on molecular & cellar biology and their transduction and evaluation system.

3. What’s more, he also was interested in recombinant enzymes from expression and microorganisms cellar factories by systems biology of natural strains and genetic/protein engineering of key enzymes under help of bioinformatics, and carried out their modification and preparation.

Recent publications:

1. GuoyingDai, Wenyun Zheng, Xingyuan Ma*.Multisite Mutation of Monomer Survivin with Enhanced Effect on Apoptosis Regulation of Breast Cancer Cells. Biomed Pharmacother.2015,69(2):111-118

2. Tianwen David Wang & Fei Ma & Xingyuan Ma. Spatially programmed assembling of oxidoreductases with single-stranded DNA for cofactor-required reactions. Appl Microbiol Biotechnol. 2015,99(8):3469-3477

3. Fei Ma,Tianwen Wang, Xingyuan Ma*. Identification and Characterization of the Protein Encoded by orf382 as an L-Threonine Dehydrogenase. J. Microbiol. Biotechnol. 2014, 24(6): 748–755

4. Liqun Wang, Yanyan Kang, Wenyun Zheng*, Linfeng Li, Lei Shi, Xingyuan Ma.Effect on apoptosis and cell cycle of recombinant double negative 4 dominant mutation Survivin (T34/117A) in breast cancer cell B-Cap-37. Biomedicine & Pharmacotherapy, 2014, 68(3):277–284

5. Nanjing Lin, Wenyun Zheng, Linfeng Li, Xingyuan Ma*, A novel system enhancing the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung cancer A549 cells. Targeted Oncology. 2014, 9(2): 163-170

6. Tianwen Wang, Xingyuan Ma*, Hu Zhu, Aitao LI, Guocheng Du, Jian Chen. Available methods for assembling expression cassettes for synthetic biology. Applied Microbiology and Biotechnology. Appl Microbiol Biotechnol (2012) 93:1853–1863

7. Rijun Gui, Xueqin An?, Hongjuan Su, Weiguo Shen, Linyong Zhu, Xingyuan Ma, Zhiyun Chen, Xiaoyong Wang..Rhodamine 6G conjugated-quantum dots used for highly sensitive and selective ratiometric fluorescence sensor of glutathione. Talanta, 94 (2012) 295-300

8. Yuxin Xu, Wenyun Zheng, Tianwen Wang, Ling Zhu, Xingyuan Ma*. Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cell lines as a synergistic drug to doxorubicin. Biomedicine & Pharmacotherapy, 2012, 66(5):368–372

9. Hailong Chen, Xingyuan Ma*, Zhi Li, Qiaoyun Shi, Wenyun Zheng, Yang Liu. Functionalization of single-walled carbon nanotubes enables efficient intracellular delivery of siRNA targeting MDM2 to inhibit breast cancer cells growth. Biomedicine & Pharmacotherapy, 2012, 66(5):334–338

10. Wang T, Ma X*, Du G, Chen J. Overview of Regulatory Strategies and Molecular Elements in Metabolic Engineering of Bacteria. Mol Biotechnol. 2012 Feb 23. [Epub ahead of print]PMID: 22359157 DOI 10.1007/s12033-012-9514-y

11. Dan Qiu, Xueqin An?, Zhiyun Chen, Xingyuan Ma. Microstructure study of liposomes decorated by hydrophobic magnetic nanoparticles. Chemistry and Physics of Lipids 165 (2012) 563-570

12. Wang T, Li A, Ma X*, DU G, Chen J. A simple and universal method to express protein in unfused form. Protein Pept Lett. 2012, 19(9):930-933

13. Wenyun Zheng, Yanyan Kang, Linfeng Li, Yuxin Xu, Xingyuan Ma*, Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discoveries & Therapeutics. 2011; 5(6):293-298

14. Xingyuan Ma, Bi Yao, Wenyun Zheng, Linfeng Li*. Comparative study on characterization of recombinant B subunit of E. coli heat-labile enterotoxin (rLTB) prepared from E. coli and P. patoris. J. Microbiol. Biotechnol. 2010, 20(3):550-557

15. Haiyi Zhang, Yu Zheng, QinghaiLiu, Xinyi Tao, Wenyun Zheng, Xingyuan Ma*, Dongzhi Wei*. Development of a fed-batch process for the production of anticancerdrug TATm-survivin(T34A) in Escherichia coli. Biochemical Engineering Journal. 2009, 43(2):163–168

16. Li Zhao, Yu Zheng, Xingyuan Ma* and Dongzhi Wei*. Effects of over-expression of glycerol dehydrogenase and 1, 3-propanediol oxidoreductase on bioconversion of glycerol into 1, 3-propandediol by Klebsiella pneumoniae under micro-aerobic conditions. Bioprocess and Biosystems Engineering, 2009, 32(3): 313-320

17. Li Zhao, Xingyuan Ma, Yu Zheng, Jianguo Zhang, Guodong Wei, Dongzhi Wei. Over-expression of glycerol dehydrogenase and 1, 3-propanediol oxidoreductase in Klebsiella pneumoniae and their effects on conversion of glycerol into 1, 3-propanediol in resting cell system. Journal of Chemical Technology & Biotechnology. 2009, 84(4): 626-632

18. Yu Zheng, Li Zhao, Xingyuan Ma, Dongzhi Wei*. Production of 1, 3-propanediol from glucose by co-expressing glycerol-3-phosphate dehydrogenase and glycerol-3-phosphatase in Klebsiella pneumoniae. Journal of Bioscience and Bioengineering, 2008, 105 (5): 508–512.

19. Xingyuan Ma, Meiyun Liu, Yushu Ma, Yi Gong *, Dongzhi Wei*, Shengli Yang. Disulfide bond Cys30-Cys299 and the fragment “96RIMQAPLT106”of the lid region of lip2 are critical for its biocatalytic activity. Journal of Biotechnology. 2008, S290-334 (V1-Y-046)

20. Xingyuan Ma*, Wenyun Zheng，Haiyi Zhang，Xinyi Tao，Qinghai Liu，Dongzhi Wei*. Large scale preparation and characterization of a genetically engineering protein and biological activity of suppressing proliferation and rapid pro-apoptosis to carcinoma cells. Journal of Biotechnology. 2008, S75-S98 (13-P-022)

21. Yu Zheng, Li Zhao, Haiyi Zhang，Liujin Wei, Xingyuan Ma, Dongzhi Wei*.one-step production of 2,3-butanediol from starch by secretory over-expression of amylase in Klebsiella pneumoniae. Journal of Chemical Technology & Biotechnology. 2008, 83: 1409-1412

22. Qinghai Liu, Jinping Lin, Meiyun Liu, Xinyi Tao, Dongzhi Wei, Xingyuan Ma and Shengli Yang Large scale preparation of recombinant human parathyroid hormone 1–84 from Escherichia coli. Protein Expression and Purification, 2007, 54: 212-219

23. Xingyuan Ma, Wenyun Zheng, Dongzhi Wei, Yushu Ma, Tianwen Wang, Jinzhi Wang, Qinghai Liu and Shengli Yang. Construction, Expression, and Purification of HIV-TAT-survivin (T34A) mutant: a Pro-apoptosis protein in E.coli. Protein Expression and Purification, 2006, 47:36-44.

24. Xingyuan Ma, Jianhua Tan, Dongzhi Wei, Pin Zhu, Manji Sun. High-level secretion and purification of recombinant acetylcholinesterase from human brain in P. pastoris and identification by chromogenic reaction. Applied Microbiology and Biotechnology. 2006, 72: 316-322.

25. Ma Xingyuan, Zheng Wenyun, Wei Dongzhi, Ma Yushu, Wang Tianwen, Wang Jinzhia, Liu Qinghai, Yang Shengli, High-level Expression, Purification and Pro-apoptosis Activity of HIV-TAT-Survivin (T34A) Mutant to Cancer Cells in Vitro, Journal of Biotechnology, 2006, 123:367-378.

26. Xingyuan Ma, Wenyun Zheng, Tianwen Wang, Dongzhi Wei, Yushu Ma. Optimization and high-level expression of a functional GST-tagged rHLT-B in E. coli and GM1 binding ability of purified rHLT-B. Journal of Microbiology, 2006, 44(6): 293-300.

27. Xingyuan Ma, Zheng Wenyun, Tianwen Wang. Leukocyte function-associated antigen-1 structure, function and application prospects. Protein and Peptide Letters, 2006, 13: 397-400.

28. Tianwen Wang, Hu Zhu, Xingyuan Ma, Yushu Ma and Dongzhi Wei. Mutant library construction in directed molecular evolution: casting a net wider. Mol Biotechnol. 2006, 34(1): 55-68.

29. Tianwen Wang, Hu Zhu, Xingyuan Ma, Yushu Ma and Dongzhi Wei. Structure-based stabilization of an enzyme: the case of penicillin acylase from Alcaligenes faecalis. Protein Peptide Letters, 2006, 13 (2):177-183.

30. Tianwen Wang, Hu Zhu, Xingyuan Ma, Zhuoya Fei, Yushu Ma and Dongzhi Wei. Enhancing enzymatic activity of penicillin G acylase by coexpressing pcm gene. Applied Microbiology and Biotechnology, 2006, 72(5): 953-958.

Research Projects or Scientific Foundation:

Oct.2014-Dec.2016 Applicant	Science and technology innovation action plan of Shanghai (14431904300)
Oct.2013-Dec.2015 Applicant	Shanghai Pujiang Program (13PJD012)
Oct.2009-Dec.2013 Applicant	The Fundamental Research Funds for the Central Universities from Education Ministry of China (Accession number: WK0913002)
Jan.2009-Dec.2010 Applicant	“A Study on Novel Drug” on the National Science Research Project "Significant New Drugs Created" of Eleventh Five-year Plan (Accession number: 2009ZX09103-693)
Jan.2009-Dec.2010 Participant	A Study on Key Technology of Novel Drug Manufacture” on the National Science Research Project "Significant New Drugs Created" of Eleventh Five-year Plan (Accession number: 2009ZX09103-001)
Jan.2009-Dec.2011 Applicant	“A study aiming to solve key and basic problems of an anticancer protein drug” By supported by the National Nature Science Foundation of China (Accession number: 30873190)
Jan.2009-Dec.2011 Second Applicant	“A study on Functions and Molecular mechanism of an Chinese traditional anticancer drug” By supported by the National Nature Science Foundation of China (Accession number: 30870253)
Jan.2008-Dec.2009 Applicant	“Molecular mechanism of TAT-Survivin mutant to breast cancer”, supported by the foundation for young teacher from Education Ministry of China (Accession number: 20070251011).
Jul.2005-Dec.2007 Applicant	“State first-class creative engineered anticancer drug TAT-Survivin mutant: pilot scale and pre-clinic research”, supported by the Key Project of Science and Technology Committee of Shanghai City (Accession number: 054319928).
Dec.2004-Aug.2005 Main Participant	“Developing the platform technology for large-scale preparation of protein drugs from microbe”, supported by the Chinese National “863”High Tech Project Foundation grant (Accession number: 2004AA2Z3801).
Jul. 2005-Dec. 2006 Applicant	“Construction of environment-friendly expression system based on the PFLD1 promoter from Pichia pastoris”, supported by the Nature Science Foundation of Shanghai. (Accession number: 05ZR14033).
Nov.2005-Oct.2007 Applicant	“Studies on pharmacodynamics and pharmacology of a novel anticancer drug for breast cancer by skin administration” was supported by Initiation Foundation for Introduced Talent of East China University of Science and Technology. (Accession number: YF0142120).
Jul. 2000-Jun. 2003 Applicant	“Studies on cDNA Cloning of Human Brain AChE and High Expression in Pichia Pastoris” was “15th” Key Research Projects of Medicine and Hygiene of PLA (Accession number: 01-Z-023).
Dec.1999-Aug.2002 Main Participant	“Studies on a bio-missile LHRH-PE40 of novel anticancer recombinant protein drug”, supported by Jilin Yatai Co., Ltd. and the Chinese National “863”High Tech Project Foundation grant.
Jul.2000 - Dec.2002 Applicant	“The establishment of detect technology for the enterotoxin gene of ST and LT from E. coli by multiplied PCR” was supported by “Science Fund For Youth” of Agricultural University of Shenyang (Accession number: 2000-17-A).
Jul.1997 - Dec.1999 Applicant	“Studies on PCR Site-directed Mutagenesis in the Cloned LT Gene and Construction of Recombinant Expression Plasmid” was supported by Quartermaster University of PLA.

MyOpenWetWare: http://openwetware.org/wiki/User:Ford_Xingyuan_Ma